Eichenfield LF et al.
- June 2024 - Journal American Academy Derma
According to this study, long-term intermittent use of ruxolitinib 1.5% cream is well tolerated and allows control of atopic dermatitis in adolescent patients.
Lawrence F. Eichenfield, University of California at San Diego, and colleagues evaluated the safety and efficacy of cream versus vehicle using aggregate data from phase 3 studies. The analysis included 245 adolescents (aged 12 to 17 years) with AD for at least two years. The researchers found that at week 8, substantially more patients who had applied the 1.5 percent ruxolitinib cream compared with vehicle had significantly higher Investigative Global Assesment (IGA) scores (50.6 vs. 14.0 percent), ≥75 percent improvement in eczema area and severity index (60.9 vs. 34.9 percent), and at least a 4-point improvement in the numeric itch rating scale (52.1 vs. 17.4 percent). Application site reactions during the 52-week period occurred in 1.8 percent of participants who applied ruxolitinib cream to 1.5 percent. No patients reported any serious adverse events.
- July 09, 2024
FDA approves Zoryve for the treatment of atopic dermatitis in adults and children
FDA approved Zoryve cream (roflumilast) 0.15% for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients aged 6 years and older